RE: £12 min on p4 and pediatric 17 May 2026 19:17
Alde - I've been in avacta for 6 years. Never underestimate their ability to snatch defeat from the Jaws of victory, like with the lft, medusa 19, bams testing, ava3996, coris, affimers, daewong and LG chem partnerships, Als infamous webinar. Avacta are nearer the finish line than Hemo, but both still have a long way to go, I'm sure both companies will come good though. Whichever one comes in first I'll probably end up buying shares with the proceeds in the other anyway.
If Hemo find no DLT at full dose level, and signs of efficacy by end of the year, then the handbrake is off, and financing the rest of the trial will be much easier and less dilutive. Hopefully vlad has plans in place to proceed with a partner for phase 2 on attractive terms to shareholders.